An observational study in Esophageal Cancer, sponsored by Fudan University. Recruiting at 11 sites in China. Per ClinicalTrials.gov, last updated 2023-07-13.
Sponsored by Fudan University · Observational
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis. Pleural lavage cytology (PLC) is reported to be associated with disease recurrence and patient survival in lung cancer, but the value is unclear in esophageal cancer. The aim of this study is to evaluate the value of PLC in esophageal cancer patient in terms of frequencies, association with patient survival, and efficacy of postoperative treatment.
Pleural lavage cytology will be performed before esophageal resection, and after resection, respectively. Frequency of positive pleural lavage cytology will be determined, and the value of pleural lavage cytology for patients with resectable esophageal cancer will be studied.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's planned enrollment of 385 is above the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with esophageal cancer
Exclusion Criteria:
pleural lavages before tumor resection and after tumor resecion, respectively
number of patients who had positive pleural lavage cytology
Frequency of positive pleural lavage cytology in resectable esophageal squamous cell carcinoma
Time frame: July 2022 to July 2023
Time period from date of surgery to the date of death
value of pleural lavage cytology in predict patient survival
Time frame: July 2022 to July 2026
Plan to share: Undecided — individual participant data could be shared after the recruitment of all 385 patients
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fudan University